Our proprietary phospholipid ether (PLE) platform technology features include the ability to link to a wide variety of oncologic therapeutic molecules, provide a significant increase in targeted delivery of molecules and targeting of all tumor cells. As a result, we are working to generate Phospholipid Drug Conjugates™ (PDCs) to treat a broad range of cancers with the potential to improve the therapeutic index of potential cancer therapies, enhance or maintain efficacy while reducing adverse events (side effects) by minimizing drug delivery to healthy cells, and increasing delivery to cancer cells and cancer stem cells.
Indication | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Pivotal | Collaboration Partner |
---|---|---|---|---|---|---|---|
Iopofosine |
Waldenstrom macroglobulinemia (WM) |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Pivotal Phase in progress
|
|
Highly Refractory Multiple Myeloma |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Pivotal Phase not-started
|
||
Pediatric |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
||
Head & Neck (IIS) |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
![]() |
|
CLR 1900 |
Solid Tumors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
|
CLR 2000 |
Solid Tumors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
![]() |
CLR 12120 |
Solid Tumors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
![]() |
New PDC's |
Various targets |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
![]() |
Various targets |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not-started
|
Phase 2 Phase not-started
|
Pivotal Phase not-started
|
![]() |
Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM.
View Iopofosine
The CLR 1900 series is another internally developed PDC program leveraging a novel class of small molecule cytotoxic compounds as the molecule. The molecule functions by targeting a validated pathway that results in stopping cell division which kills the tumor cells. This series of molecules could produce a product candidate that can treat certain solid tumors. Currently, the program is in early preclinical development.
CLR 2000 series is part of a collaborative PDC program with Avicenna Oncology, a leading developer of antibody drug conjugates (ADCs). The objective of the research collaboration is to design and develop a series of PDCs utilizing Avicenna Oncology’s proprietary cytotoxic warhead. Although Avicenna Oncology is a leading developer of ADCs, this collaboration was sought to overcome many of the challenges associated with ADCs, including those associated with the targeting of specific cell surface epitopes.
The CLR 12120 Series is a collaborative PDC program with Orano Med for the development of novel PDCs utilizing Orano Med’s unique alpha emitter, lead 212 conjugated to our phospholipid ether; the companies intend to evaluate the new PDCs in up to three oncology indications.
The yet to be named series is a collaboration combining IntoCell’s validated novel Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker chemistry with Cellectar’s validated novel targeting platform, phospholipid ethers (PLEs) to develop new PDCs. IntoCell’s platform significantly enhances the utility of traditional antibody drug conjugate linkers by customizing the entire linker to a specific project. The collaboration has exceeded the necessary preclinical results to warrant further development and the initiation of Investigational New Drug (IND) enabling studies with multiple payloads. Cellectar will have the right to globally develop and commercialize any OHPAS containing PDC.
Under the agreement, the Cellectar Biosciences and LegoChemBio have the option to jointly develop three new small molecule PDCs utilizing Cellectar’s proprietary drug targeting platform, phospholipid ether (PLE) technology and LegoChemBio’s proprietary drug conjugate linker-toxin platform. The co-development option is exercisable at defined points with either party allowed to acquire full global commercialization rights. The parties have further agreed to focus development of the drug candidates on solid tumors with significant unmet medical need and potential for accelerated regulatory pathways. Details of the financial terms of the agreement have not been disclosed.